# Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)

> **NCT02952820** · PHASE3 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 971 (actual)

## Conditions studied

- Insomnia Disorder

## Interventions

- **DRUG:** lemborexant
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02952820
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-15
- **Primary completion:** 2019-01-08
- **Final completion:** 2019-01-08
- **Target enrollment:** 971 (ACTUAL)
- **Last updated:** 2020-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952820, "Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02952820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*